


Targeted Funding Announcements



What Are They and Why Does PCORI Fund Them?

Through PCORI Funding Announcements (PFAs) focused on specific high-impact topics, we seek to produce evidence that will have a substantial impact on practice and patient outcomes.

The comparative clinical effectiveness research (CER) projects funded through our targeted PFAs are often larger and run for a longer period than those selected through our more general calls for proposals.

We identify the topics through our systematic topic generation and research prioritization process. It begins with potential research questions that come directly from patients and other stakeholders. We evaluate the questions with input from our Board of Governors, Science Oversight Committee, advisory panels, and multi-stakeholder workshops.

As of July 2018, PCORI has approved

\$1.62 BILLION TO FUND 431
comparative clinical effectiveness research (CER) studies.

TOPICS

Approved projects study topics that include the following:



INJURIES FROM
FALLS



CHRONIC PAIN/
OPIOID USE



SICKLE CELL
DISEASE



HYPERTENSION



TREATMENT-
RESISTANT
DEPRESSION



OBESITY



MULTIPLE
SCLEROSIS



HEPATITIS C



TRANSITIONAL
CARE

Funding Opportunities

We are currently seeking applications through three targeted PFAs, which offer funding of

- Up to \$25 million for studies comparing [*psychosocial interventions with office-based opioid treatment for opioid use disorder*](#).
- Up to \$22 million for studies on [*symptom management for patients with advanced illness*](#).
- Up to \$6 million for studies on [*medication-assisted treatment \(MAT\) delivery for pregnant women with substance use disorders involving prescription opioids and/or heroin*](#).

Studies Under Way

We have approved dozens of CER studies for funding through targeted PFAs. We made some of these awards in partnership with other organizations.

TARGETED PFA STUDIES	NUMBER OF AWARDS	FUNDING AMOUNTS
Community-Based Palliative Care Delivery for Adult Patients with Advanced Illnesses and Their Caregivers	Seven	\$73 Million
Comparing Treatment Strategies for Multiple Sclerosis	Nine	\$58 Million
Comparing Management Strategies for Treatment-Resistant Depression	Three	\$40 Million
Examining the Safety and Effectiveness of Clinical Strategies for Managing and Reducing Long-Term Opioid Use for Chronic Pain	Four	\$39 Million
Testing a Serious-Fall Prevention Strategy in Older Adults	One	\$30 Million
Comparing Diagnosis and Treatment Strategies for Hepatitis C Infection	Two	\$26 Million
Treatment Options for African Americans and Hispanics/Latinos with Uncontrolled Asthma	Eight	\$23 Million
Testing Multilevel Interventions to Improve Blood Pressure Control in High-Risk Populations	Two	\$22 Million
Comparing the Risks and Benefits of New Oral Anticoagulants (NOACs) in the Extended Treatment of Venous Thromboembolic Disease	Three	\$21 Million
Determining Which Obesity Treatments Achieve the Best Weight-Loss Results in People at Risk for Health Disparities	Two	\$20 Million
Developing a Registry in Support of Treatment Options for Uterine Fibroids	One	\$20 Million
Management of Sickle Cell Disease in Youths	Two	\$18 Million
Comparing the Effectiveness of Usual Care and Transitional Care for At-Risk Populations	One	\$15 Million
Comparing Surgical and Nonsurgical Options for Low Back Pain	One	\$10 Million
Medication-Assisted Treatment for Pregnant Women with Substance Use Disorders	Two	\$10 Million
Strategies to Prevent Unsafe Opioid Prescribing	Two	\$10 Million
Natural Experiments Network for Diabetes	Three	\$7 Million
Symptom Management for Patients with Advanced Illness	One	\$3 Million

As with all PCORI projects, these studies were approved by our Board subject to a business and programmatic review by PCORI staff and completion of a final research contract.